Literature DB >> 3780143

Treatment of Behçet's disease with thalidomide.

M H Hamza.   

Abstract

The clinical response to thalidomide in 30 male patients with Behçet's disease was reviewed. Twenty-six patients with orogenital ulcerations responded (20 completely and 6 partially). Cutaneous lesions including erythema nodosum or necrotic pseudofolliculitis were controlled by treatment in the majority of cases. All patients with arthritis responded (13 completely and 1 partially). Uveitis was improved in 3 patients, stabilizated in 4 and aggravated in 4. Patients with thalidomide purposely discontinued experienced a flare; the reintroduction of therapy controlled the flare. Side effects were uncommon and included skin rash and somnolence. These results suggest that thalidomide may be useful in the therapy of the various manifestations of Behçet's disease and that a controlled study is indicated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780143     DOI: 10.1007/bf02054255

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS.

Authors:  J SHESKIN
Journal:  Clin Pharmacol Ther       Date:  1965 May-Jun       Impact factor: 6.875

2.  PROLONGATION OF SKIN HOMOGRAFT SURVIVAL BY THALIDOMIDE.

Authors:  K HELLMANN; D I DUKE; D F TUCKER
Journal:  Br Med J       Date:  1965-09-18

3.  [Thalidomide and the treatment of Behçet's syndrome].

Authors:  P Couzigou; M S Doutre; G Houdée; B Richard-Molard; B Fleury; M Amouretti; C Beylot; C Béraud
Journal:  Gastroenterol Clin Biol       Date:  1983 Aug-Sep

4.  [Speculative ameloriation of arthritis in Behcet disease with thalidomide. A case report].

Authors:  R Trèves; M Arnaud; P Jacob; M Lubeau; F Tabaraud; F Burki; R Desproges-Gotteron
Journal:  Rev Rhum Mal Osteoartic       Date:  1984-11

5.  Treatment of Behcet's disease with levamisole.

Authors:  M Hamza; K Ayed; H Ben Ayed
Journal:  Arthritis Rheum       Date:  1982-06

6.  Thalidomide treatment of subacute cutaneous lupus erythematosus.

Authors:  B Naafs; E J Bakkers; J Flinterman; W R Faber
Journal:  Br J Dermatol       Date:  1982-07       Impact factor: 9.302

7.  Development of polyneuropathy during thalidomide therapy.

Authors:  C H Wulff; H Høyer; G Asboe-Hansen; H Brodthagen
Journal:  Br J Dermatol       Date:  1985-04       Impact factor: 9.302

8.  Thalidomide. A promising new treatment for rheumatoid arthritis.

Authors:  O Gutiérrez-Rodríguez
Journal:  Arthritis Rheum       Date:  1984-10

9.  Chlorambucil in Behçet's disease. A reappraisal.

Authors:  K F Tabbara
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

10.  Functional aberration of T cell subsets in patients with Behçet's disease.

Authors:  T Sakane; H Kotani; S Takada; T Tsunematsu
Journal:  Arthritis Rheum       Date:  1982-11
View more
  19 in total

1.  Intestinal Behçet's disease presenting as a massive acute lower gastrointestinal bleed.

Authors:  Jeffrey A Smith; Dabir Siddiqui
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

Review 2.  Thalidomide embryopathy: a model for the study of congenital incomitant horizontal strabismus.

Authors:  M T Miller
Journal:  Trans Am Ophthalmol Soc       Date:  1991

Review 3.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 4.  Teratogenic effects of thalidomide: molecular mechanisms.

Authors:  Takumi Ito; Hideki Ando; Hiroshi Handa
Journal:  Cell Mol Life Sci       Date:  2011-01-05       Impact factor: 9.261

5.  Treatment of Behçet's disease with dapsone.

Authors:  M Hamza; K Hamzaoui; K Ayed
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

6.  Thalidomide and cell mediated immunity in Behçet's disease.

Authors:  M Hamza; K Hamzaoui; K Ayed; M Eleuch; A Zribi
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

7.  Natural killer cells in Behçet's disease.

Authors:  K Hamzaoui; K Ayed; M Hamza; J L Touraine
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

Review 8.  Thalidomide in gastrointestinal disorders.

Authors:  A Bousvaros; B Mueller
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 9.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

10.  Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease.

Authors:  H Direskeneli; T Ergun; S Yavuz; V Hamuryudan; E Eksioglu-Demiralp
Journal:  Clin Rheumatol       Date:  2007-11-23       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.